Listed by the USPTO as RAO, PADMAJA S
Tech Center 1600 • Art Units: 1627
This examiner grants 71% of resolved cases
RAO, PADMAJA S is assigned to Tech Center 1600 and Art Unit 1627. The profile covers 161 resolved cases, with an allowance rate of 70.8% and a median of 1114 days to allowance. The interview lift is 36.5%, indicating a meaningful measured association between interviews and allowance outcomes.
Enyo Pharma, The Regents of the University of California, and Massachusetts Institute of Technology are the leading companies or institutions represented. The leading firms are SALIWANCHIK, LLOYD & EISENSCHENK, BakerHostetler, and BALLARD SPAHR LLP. Practitioners may wish to pair focused claim work with interview preparation, while accounting for the median prosecution timeline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18551428 | Compositions and Methods for Inhibiting and Treating Viral Infections | Non-Final OA | The Regents of the University of California |
| 18065348 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | Non-Final OA | Massachusetts Institute of Technology |
| 18251079 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Non-Final OA | AbbVie Inc. |
| 18699188 | PYRAZOLE COMPOUNDS AND USES THEREOF | Non-Final OA | ALCON INC. |
| 17291055 | COMPOSITIONS AND METHODS USING A COMBINATION OF CURCUMIN AND AN OMEGA-3 FATTY ACID FOR CELLULAR ENERGY | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 17770686 | USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR PREVENTION, ALLEVIATION, OR TREATMENT OF COGNITIVE DISORDERS, OR FOR IMPROVING COGNITIVE FUNCTION | Final Rejection | SK BIOPHARMACEUTICALS CO., LTD. |
| 17791110 | A METHOD OF TREATMENT IN PREDISPOSED SUBJECTS FOR LMNA-RELATED DILATED CARDIOMYOPATHY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18043163 | HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF | Non-Final OA | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF VETERANS AFFAIRS |
| 18566176 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | Final Rejection | VERTEX PHARMACEUTICALS INCORPORATED |
| 18692018 | PROCESS FOR PREPARING 5-FLUORO-4-IMINO-3-METHYL-1-(TOLUENE-4- SULFONYL)-3,4-DIHYDRO-1H-PYRIMIDIN-2-ONE | Non-Final OA | Adama Makhteshim Ltd. |
| 18351359 | INJECTABLE METHODS TO TREAT DEFICIENCIES IN GLUTATHIONE METABOLISM AND HOMOCYSTINURIA | Non-Final OA | Individual inventor |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy70.8% of resolved applications examined by Padmaja S Rao were allowed (161 resolved cases), compared with 35.4% across Art Unit 1627 over the last five years.
This examiner's interview lift is +36.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Padmaja S Rao took 1,114 days on average from filing to allowance.
Padmaja S Rao examines applications in Art Unit 1627 in Tech Center 1600 (Biotechnology & Pharmaceuticals).